Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients

Abstract

Background: Chronic myeloproliferative diseases are clonal stem cell diseases which occur as a result of uncontrollable growth and reproduction of hematopoietic stem cells, which are the myeloid series source in bone marrow. Recent studies have suggested that chronic inflammation can be a triggering factor in the clonal change in chronic myeloproliferative neoplasia (CMPN). In our study, we evaluated the existence of a chronic inflammation process in our Philadelphia negative (Ph-)CMPN patients using inflammation parameters in combination with demographic, laboratory and clinical characteristics of the patients. Materials and Methods: Demographic characteristics, clinical and laboratorial data, and thrombosis histories of 99 Ph-CMPN patients, who were diagnosed at our outpatient clinic of hematology in accordance with WHO 2008 criteria, were analyzed retrospectively,with 80 healthy individuals of matching gender and age included as controls. Complete blood counts, sedimentation, C reactive protein (CRP), JAK V617F gene mutations, abdomen ultrasound images and previous thrombosis histories of these patients were retrospectively analyzed. Results: Ph-CMPN and healthy control groups included 99 and 80 cases, respectively. PV, ET and MF diagnoses of patients were 43 (%43.4), 44 (44.4%) and 12 (12.1%), respectively. JAK V617F gene mutation was found to be positive in 64 (71.1%) of all cases and in 27(65.8%), 32 (82%), 5 (50%) of the cases in PV, ET and PMF groups, respectively. Thrombosis was determined as 12 (12%) in the entire group, 12.5% in the JAK V617F negative and 15.3% in the positive patients, with no statistical significance (p=0.758). No significant difference was observed between patients with and without previous thrombosis history in respect to hemogram parameters, sedimentation and CRP (p>0.05), neutrophil to lymphocyte ratio (NLR), erythrocyte distribution width (RDW), mean platelet volume (MPV) and sedimentation levels of the patient.

<p>The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies – A Narrative Review</p>

“…No significant difference has been found between thrombosis history and NLR value. 122 It seems that in myeloproliferative malignancies, oxidative stress is of great importance as a mechanism of tumorigenesis. [123][124][125] This reflects an imbalance between overproduction of reactive oxygen species and the cellular antioxidant defense.…”

Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio patients with giant cell tumor of bone

“…GCT is a local destructive tumor of mesenchymal stromal cells; monocytic, mononuclear cells of myeloid lineage; and characteristic osteoclast-like, multinucleated giant cells 29 . It was observed that elevated levels of NLR were determined in patients with myeloproliferative neoplasms which were in the same stromal group of cells as GCT 30 , 31 . Besides, the prognostic role of NLR has been documented in multiple cancers from different stem cell lineage-based solid tumors like ovarian, breast, kidney, lung, colorectal 32 , 33 .…”

Elevated Neutrophil–to–Lymphocyte-ratio and Platelet–to–Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?

“…We could not identify prior studies investigating NLR or PLR in a population of myelofibrosis patients. However, two smaller studies assessed NLR/PLR in different Ph-MPN cohorts (33,34). First study (33) suggested that NLR (among other inflammatory parameters) was elevated in a heterogenous cohort of Ph-MPN patients, which is in line with our findings of increased NLR in a population of myelofibrosis patients.…”